Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01009840 · OUTCOME

Overall Survival

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients · Source last updated 2026-05-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
6 Months

What was measured

Esimated overall survival rate (percentage of participants) at Day 180

Analysis population: Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.

Groups in this outcome

IV Busulfan

Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IV Busulfan30

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IV Busulfan85.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        85.9
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Esimated overall survival rate (percentage of participants) at Day 180
groups
  1. description
    Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
    id
    OG000
    title
    IV Busulfan
param Type
NUMBER
population Description
Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.
reporting Status
POSTED
time Frame
6 Months
title
Overall Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice